Raras
Buscar doenças, sintomas, genes...
Taquicardia ventricular polimórfica catecolaminérgica
ORPHA:3286CID-10 · I47.2CID-11 · BC65.5DOENÇA RARA

A Taquicardia Ventricular Polimórfica Catecolaminérgica (CPVT) é um distúrbio cardíaco genético grave que causa arritmias, ou seja, alterações no ritmo do coração. Ela é caracterizada por episódios de taquicardia ventricular (TV), que são batimentos cardíacos muito rápidos e desorganizados vindos dos ventrículos do coração. Esses episódios são geralmente desencadeados por situações de estresse, exercício físico ou fortes emoções, que aumentam a adrenalina. A CPVT pode se manifestar como desmaios e, em casos mais sérios, pode levar à morte súbita.

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

A Taquicardia Ventricular Polimórfica Catecolaminérgica (CPVT) é um distúrbio cardíaco genético grave que causa arritmias, ou seja, alterações no ritmo do coração. Ela é caracterizada por episódios de taquicardia ventricular (TV), que são batimentos cardíacos muito rápidos e desorganizados vindos dos ventrículos do coração. Esses episódios são geralmente desencadeados por situações de estresse, exercício físico ou fortes emoções, que aumentam a adrenalina. A CPVT pode se manifestar como desmaios e, em casos mais sérios, pode levar à morte súbita.

Pesquisas ativas
8 ensaios
18 total registrados no ClinicalTrials.gov
Publicações científicas
1.298 artigos
Último publicado: 2026 Apr 16

Escala de raridade

CLASSIFICAÇÃO ORPHANET · BRASIL 2024
1-5 / 10 000
Ultra-rara
<1/50k
Muito rara
1/20k
Rara
1/10k
Pouco freq.
1/5k
Incomum
1/2k
Prevalência
10.0
Europe
Início
Adolescent
+ adult, childhood
🏥
SUS: Sem cobertura SUSScore: 0%
CID-10: I47.2
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

❤️
Coração
19 sintomas
🧠
Neurológico
1 sintomas
💪
Músculos
1 sintomas

+ 11 sintomas em outras categorias

Características mais comuns

90%prev.
Taquicardia ventricular
Muito frequente (99-80%)
55%prev.
Parada cardíaca
Frequente (79-30%)
55%prev.
Taquicardia supraventricular
Frequente (79-30%)
55%prev.
Vertigem
Frequente (79-30%)
55%prev.
Palpitações
Frequente (79-30%)
55%prev.
Fibrilação atrial
Frequente (79-30%)
32sintomas
Muito frequente (1)
Frequente (6)
Ocasional (3)
Sem dados (22)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 32 características clínicas mais associadas, ordenadas por frequência.

Taquicardia ventricularVentricular tachycardia
Muito frequente (99-80%)90%
Parada cardíacaCardiac arrest
Frequente (79-30%)55%
Taquicardia supraventricularSupraventricular tachycardia
Frequente (79-30%)55%
VertigemVertigo
Frequente (79-30%)55%
PalpitaçõesPalpitations
Frequente (79-30%)55%

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Total histórico1.298PubMed
Últimos 10 anos200publicações
Pico202588 papers
Linha do tempo
2026Hoje · 2026🧪 2011Primeiro ensaio clínico📈 2025Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

7 genes identificados com associação a esta condição. Padrão de herança: Autosomal dominant, Autosomal recessive.

RYR2Ryanodine receptor 2Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Cytosolic calcium-activated calcium channel that mediates the release of Ca(2+) from the sarcoplasmic reticulum into the cytosol and thereby plays a key role in triggering cardiac muscle contraction. Aberrant channel activation can lead to cardiac arrhythmia. In cardiac myocytes, calcium release is triggered by increased Ca(2+) cytosolic levels due to activation of the L-type calcium channel CACNA1C. The calcium channel activity is modulated by formation of heterotetramers with RYR3. Required fo

LOCALIZAÇÃO

Sarcoplasmic reticulum membrane

VIAS BIOLÓGICAS (2)
Ion homeostasisStimuli-sensing channels
MECANISMO DE DOENÇA

Ventricular tachycardia, catecholaminergic polymorphic, 1, with or without atrial dysfunction and/or dilated cardiomyopathy

An arrhythmogenic disorder characterized by stress-induced, bidirectional ventricular tachycardia that may degenerate into cardiac arrest and cause sudden death. Patients present with recurrent syncope, seizures, or sudden death after physical activity or emotional stress. CPVT1 inheritance is autosomal dominant.

EXPRESSÃO TECIDUAL(Ubíquo)
Coração - Ventrículo esquerdo
82.3 TPM
Coração - Átrio
75.8 TPM
Cerebelo
27.9 TPM
Cérebro - Hemisfério cerebelar
26.5 TPM
Artéria tibial
18.5 TPM
OUTRAS DOENÇAS (6)
catecholaminergic polymorphic ventricular tachycardia 1ventricular arrhythmias due to cardiac ryanodine receptor calcium release deficiency syndromefamilial isolated arrhythmogenic ventricular dysplasia, left dominant formfamilial isolated arrhythmogenic ventricular dysplasia, right dominant form
HGNC:10484UniProt:Q92736
CALM3Calmodulin-3Candidate gene tested inAltamente restrito
FUNÇÃO

Calmodulin acts as part of a calcium signal transduction pathway by mediating the control of a large number of enzymes, ion channels, aquaporins and other proteins through calcium-binding (PubMed:16760425, PubMed:31454269). Calcium-binding is required for the activation of calmodulin (PubMed:16760425, PubMed:31454269, PubMed:35568036). Among the enzymes to be stimulated by the calmodulin-calcium complex are a number of protein kinases, such as myosin light-chain kinases and calmodulin-dependent

LOCALIZAÇÃO

Cytoplasm, cytoskeleton, spindleCytoplasm, cytoskeleton, spindle poleCytoplasm, cytoskeleton, microtubule organizing center, centrosome

VIAS BIOLÓGICAS (2)
CASP4 inflammasome assemblyEnterobacterial factors antagonize host defense
MECANISMO DE DOENÇA

Ventricular tachycardia, catecholaminergic polymorphic, 6

An arrhythmogenic disorder characterized by stress-induced, bidirectional ventricular tachycardia that may degenerate into cardiac arrest and cause sudden death. Patients present with recurrent syncope, seizures, or sudden death after physical activity or emotional stress. CPVT6 inheritance is autosomal dominant.

OUTRAS DOENÇAS (3)
long QT syndrome 16catecholaminergic polymorphic ventricular tachycardiafamilial long QT syndrome
HGNC:1449UniProt:P0DP25
TECRLTrans-2,3-enoyl-CoA reductase-likeDisease-causing germline mutation(s) inTolerante
LOCALIZAÇÃO

MembraneEndoplasmic reticulum

VIAS BIOLÓGICAS (1)
Synthesis of very long-chain fatty acyl-CoAs
MECANISMO DE DOENÇA

Ventricular tachycardia, catecholaminergic polymorphic, 3

An arrhythmogenic disorder characterized by stress-induced, bidirectional ventricular tachycardia that may degenerate into cardiac arrest and cause sudden death. Patients present with recurrent syncope, or sudden death after physical activity or emotional stress. CPVT3 is an autosomal recessive disorder with onset at early age and associated with sudden death in childhood. Patients manifest QT prolongation on adrenergic stimulation.

EXPRESSÃO TECIDUAL(Tecido-específico)
Coração - Ventrículo esquerdo
119.1 TPM
Coração - Átrio
112.8 TPM
Músculo esquelético
8.9 TPM
Tireoide
0.1 TPM
Glândula adrenal
0.1 TPM
OUTRAS DOENÇAS (2)
catecholaminergic polymorphic ventricular tachycardia 3catecholaminergic polymorphic ventricular tachycardia
HGNC:27365UniProt:Q5HYJ1
CALM2Calmodulin-2Candidate gene tested inAltamente restrito
FUNÇÃO

Calmodulin acts as part of a calcium signal transduction pathway by mediating the control of a large number of enzymes, ion channels, aquaporins and other proteins through calcium-binding (PubMed:16760425, PubMed:26969752, PubMed:27165696). Calcium-binding is required for the activation of calmodulin (PubMed:16760425, PubMed:26969752, PubMed:27165696, PubMed:35568036). Among the enzymes to be stimulated by the calmodulin-calcium complex are a number of protein kinases, such as myosin light-chain

LOCALIZAÇÃO

Cytoplasm, cytoskeleton, spindleCytoplasm, cytoskeleton, spindle poleCytoplasm, cytoskeleton, microtubule organizing center, centrosome

VIAS BIOLÓGICAS (2)
CASP4 inflammasome assemblyEnterobacterial factors antagonize host defense
MECANISMO DE DOENÇA

Long QT syndrome 15

A form of long QT syndrome, a heart disorder characterized by a prolonged QT interval on the ECG and polymorphic ventricular arrhythmias. They cause syncope and sudden death in response to exercise or emotional stress, and can present with a sentinel event of sudden cardiac death in infancy.

OUTRAS DOENÇAS (3)
long QT syndrome 15catecholaminergic polymorphic ventricular tachycardiafamilial long QT syndrome
HGNC:1445UniProt:P0DP24
CASQ2Calsequestrin-2Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Calsequestrin is a high-capacity, moderate affinity, calcium-binding protein and thus acts as an internal calcium store in muscle. Calcium ions are bound by clusters of acidic residues at the protein surface, especially at the interface between subunits. Can bind around 60 Ca(2+) ions. Regulates the release of lumenal Ca(2+) via the calcium release channel RYR2; this plays an important role in triggering muscle contraction. Plays a role in excitation-contraction coupling in the heart and in regu

LOCALIZAÇÃO

Sarcoplasmic reticulum lumen

VIAS BIOLÓGICAS (2)
Ion homeostasisStimuli-sensing channels
MECANISMO DE DOENÇA

Ventricular tachycardia, catecholaminergic polymorphic, 2

An arrhythmogenic disorder characterized by stress-induced, bidirectional ventricular tachycardia that may degenerate into cardiac arrest and cause sudden death. Patients present with recurrent syncope, seizures, or sudden death after physical activity or emotional stress. CPVT2 inheritance is autosomal recessive.

OUTRAS DOENÇAS (2)
catecholaminergic polymorphic ventricular tachycardia 2catecholaminergic polymorphic ventricular tachycardia
HGNC:1513UniProt:O14958
CALM1Calmodulin-1Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Calmodulin acts as part of a calcium signal transduction pathway by mediating the control of a large number of enzymes, ion channels, aquaporins and other proteins through calcium-binding (PubMed:16760425, PubMed:23893133, PubMed:26969752, PubMed:27165696, PubMed:28890335, PubMed:31454269, PubMed:35568036). Calcium-binding is required for the activation of calmodulin (PubMed:16760425, PubMed:23893133, PubMed:26969752, PubMed:27165696, PubMed:28890335, PubMed:31454269, PubMed:35568036). Among the

LOCALIZAÇÃO

Cytoplasm, cytoskeleton, spindleCytoplasm, cytoskeleton, spindle poleCytoplasm, cytoskeleton, microtubule organizing center, centrosomeCell projection, cilium, flagellum

VIAS BIOLÓGICAS (10)
Cam-PDE 1 activationFCGR3A-mediated IL10 synthesisPKA activationSmooth Muscle ContractionCa2+ pathway
MECANISMO DE DOENÇA

Ventricular tachycardia, catecholaminergic polymorphic, 4

An arrhythmogenic disorder characterized by stress-induced, bidirectional ventricular tachycardia that may degenerate into cardiac arrest and cause sudden death. Patients present with recurrent syncope, seizures, or sudden death after physical activity or emotional stress. CPVT4 inheritance is autosomal dominant.

OUTRAS DOENÇAS (4)
long QT syndrome 14catecholaminergic polymorphic ventricular tachycardia 4catecholaminergic polymorphic ventricular tachycardiafamilial long QT syndrome
HGNC:1442UniProt:P0DP23
TRDNTriadinDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Contributes to the regulation of lumenal Ca2+ release via the sarcoplasmic reticulum calcium release channels RYR1 and RYR2, a key step in triggering skeletal and heart muscle contraction. Required for normal organization of the triad junction, where T-tubules and the sarcoplasmic reticulum terminal cisternae are in close contact (By similarity). Required for normal skeletal muscle strength. Plays a role in excitation-contraction coupling in the heart and in regulating the rate of heart beats

LOCALIZAÇÃO

Cell membraneSarcoplasmic reticulum membrane

VIAS BIOLÓGICAS (2)
Ion homeostasisStimuli-sensing channels
MECANISMO DE DOENÇA

Cardiac arrhythmia syndrome, with or without skeletal muscle weakness

An autosomal recessive cardiac disorder characterized by stress-induced arrhythmias in infancy or early childhood. Patients present with recurrent syncope or cardiac arrest after physical activity or emotional stress. Sudden death may occur in early childhood. Some patients have muscle weakness.

EXPRESSÃO TECIDUAL(Tecido-específico)
Músculo esquelético
361.9 TPM
Coração - Átrio
55.6 TPM
Coração - Ventrículo esquerdo
40.6 TPM
Fallopian Tube
7.3 TPM
Pituitária
6.6 TPM
OUTRAS DOENÇAS (3)
catecholaminergic polymorphic ventricular tachycardia 5catecholaminergic polymorphic ventricular tachycardiafamilial long QT syndrome
HGNC:12261UniProt:Q13061

Variantes genéticas (ClinVar)

405 variantes patogênicas registradas no ClinVar.

🧬 TRDN: NM_006073.4(TRDN):c.295dup (p.Thr99fs) ()
🧬 TRDN: NM_006073.4(TRDN):c.793+2T>C ()
🧬 TRDN: NM_006073.4(TRDN):c.521del (p.Val174fs) ()
🧬 TRDN: GRCh37/hg19 6q22.1-22.33(chr6:114742335-127346798)x1 ()
🧬 TRDN: NM_006073.4(TRDN):c.314G>A (p.Gly105Asp) ()
Ver todas no ClinVar

Classificação de variantes (ClinVar)

Distribuição de 9,350 variantes classificadas pelo ClinVar.

5610
3740
VUS (60.0%)
Benigna (40.0%)
VARIANTES MAIS SIGNIFICATIVAS
RYR2: NM_001035.3(RYR2):c.6784C>G (p.Leu2262Val) [Uncertain significance]
TRDN: NM_006073.4(TRDN):c.272T>G (p.Leu91Arg) [Uncertain significance]
RYR2: NM_001035.3(RYR2):c.14816A>T (p.Tyr4939Phe) [Uncertain significance]
RYR2: NM_001035.3(RYR2):c.5543C>G (p.Pro1848Arg) [Uncertain significance]
CASQ2: NM_001232.4(CASQ2):c.697A>G (p.Thr233Ala) [Uncertain significance]

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
2Fase 24
1Fase 11
·Pré-clínico11
Medicamentos catalogadosEnsaios clínicos· 0 medicamentos · 16 ensaios
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Taquicardia ventricular polimórfica catecolaminérgica

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

🟢 Recrutando agora

8 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

Outros ensaios clínicos

18 ensaios clínicos encontrados, 8 ativos.

Distribuição por fase
Ver todos no ClinicalTrials.gov
🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
824 papers (10 anos)

Mostrando amostra de 200 publicações de um total de 824

#1

Ca2+ signalling in cardiac muscle: the importance of balances.

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology2026 Mar 10

In this narrative review, an example of a cardiac arrhythmia with a mechanistically appealing molecular pathomechanism is highlighted. This example will be used to delineate how recent basic science findings, which are summarized, can be used to obtain a deeper understanding of pathological behaviour from the molecular to the cellular level. The condition in question is the highly lethal catecholaminergic polymorphic ventricular tachycardia resulting from a point mutation of the cardiac ryanodine receptor. For this deep dive, the RyR2R420Q phenotype will be discussed in detail. Interestingly, these findings and the conclusions which could be drawn from them were very much unexpected but could be relevant for pharmacological treatments. To make the transition from the molecular and cellular findings to the patient will require the translation across several layers of complexity. Ultimately, such detailed understanding will lead to improved therapies tailored to each individual case and the specific RyR2 mutation carried by a particular family, in the framework of precision medicine.

#2

Generation of three heterozygous and two homozygous hiPSC lines from a CPVT associated mutation RYR2_p.G357S from a large family of the Canary Islands.

Stem cell research2026 Mar 06

Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an inherited arrhythmogenic disease characterized by adrenergically induced ventricular arrhythmias that cause sudden cardiac death. Using non-integrative episomal plasmids we reprogrammed skin fibroblasts of three heterozygous and two homozygous carriers of a mutation in the gene that encodes the ryanodine receptor type 2 (RYR2), RYR2_c.G1069A/p.G357S, previously associated to CPVT in a large family of the Gran Canaria Island. The resulting hiPSC cell lines have normal karyotype, differentiate into cells of the 3 germ layers, and express pluripotency markers and genes.

#3

Paediatric inherited arrhythmia clinic: developing a new model of care.

BMJ paediatrics open2026 Mar 09

To describe the development and utilisation of a paediatric inherited arrhythmia clinic (IAC) from 2014 to 2024, including service developments following the introduction of cardiac genetic coordinators (CGC). Retrospective cohort study. The IAC at Children's Hospital Westmead, New South Wales, Australia (approximately 8 million people). Children (aged 0-18 years) referred to the IAC. Clinical and genetic data were extracted and analysed. Description of the development and cohort of the clinic. A monthly clinic preceded by a team meeting (multidisciplinary team) led by a paediatric cardiologist and clinical geneticist was established. Attendees included a genetic counsellor, senior arrhythmia nurse and clinical psychologist.A total of 301 individuals aged 0-18 years were seen over 11 years: 32 in 2014 and 128 in 2024. 85 probands presented with cardiac arrest (37; 44%), syncope (23; 27%) and others (25; 29%). The most common diagnoses were Long QT syndrome 33 (38%), catecholaminergic polymorphic ventricular tachycardia 24 (28%) and Brugada syndrome 6 (7%). 226/301 children had genetic testing; pathogenic/likely pathogenic variants were found in 173/226 (77%), including 121 family members. The most common genes implicated were KCNQ1 (67), KCNH2 (39), SCN5A (28) and RyR2 (15).Dedicated allied health/nursing CGCs appointed in 2023 improved the collation of clinical/family data (particularly new referrals), links to adult cardiology, forensic and regional genetic and paediatric services. The multidisciplinary IAC achieves the phenotyping, genotyping and holistic care of large numbers of children, mostly with cardiac ion channelopathies. Dedicated coordinators provided an incremental improvement to the service.

#4

Bidirectional ventricular tachycardia caused by occlusion myocardial infarction-a case report.

European heart journal. Case reports2026 Feb

Bidirectional ventricular tachycardia (BdVT) is an uncommon form of ventricular arrhythmia typically associated with digoxin toxicity or catecholaminergic polymorphic ventricular tachycardia. BdVT in the setting of acute myocardial ischaemia is limited to case reports. We present an example of BdVT caused by occlusion myocardial infarction with original and modified Sgarbossa criteria being positive. An elderly male with known coronary artery disease presented with chest pain. The initial ECG demonstrated a regular wide QRS complex tachycardia with alternating frontal plane axis, consistent with BdVT. No apparent cause of the arrhythmia was identified from the patient's medication history or family history. Detailed ECG analysis revealed that during tachycardia, the QRS complexes exhibited excessively discordant ST segment elevation and depression. ST segment concordance was observed in natively conducted beats of left bundle branch block morphology following termination of the arrhythmia. These findings raised suspicion of occlusion myocardial infarction as the direct cause of BdVT. This was subsequently confirmed by coronary angiography. BdVT is a distinct form of ventricular tachycardia, characterized by beat-to-beat alternation in QRS axis and morphology. BdVT in the context of acute ischaemia is rare and limited to case reports. Although this clinical presentation is exceptionally rare, in patients with BdVT and symptoms suggestive of acute coronary syndrome, active myocardial ischaemia should be considered as a potential underlying cause. This case highlights the utility of both the original and modified Sgarbossa criteria in identifying acute ischaemia in the setting of a wide complex rhythm.

#5

Wnt pathway activation unlocks disease-neutral proliferative potential in human iPSC-derived cardiomyocytes: A comparative study across healthy and inherited cardiac disease models.

Tissue &amp; cell2026 Feb

The therapeutic potential of Wnt/β-catenin signaling to enhance proliferation in differentiated cardiomyocytes remains underexplored, particularly in genetically diverse disease models. Here, we systematically evaluated whether pharmacological Wnt activation overrides genetic constraints to drive expansion of induced pluripotent stem cell-derived cardiomyocytes (iCMs) from healthy donors and inherited cardiomyopathy models (GAA-Pompe disease, RYR2-catecholaminergic polymorphic ventricular tachycardia, and KCNQ1-long QT syndrome type 1). Using a component-defined GiWi protocol, functionally mature iCMs were generated from a high-quality iPSC line with validated trilineage differentiation capacity. Longitudinal analysis of CHIR-induced Wnt/β-catenin activation demonstrated dose-dependent proliferative amplification, with CHIR-treated iCMs achieving > 400-fold monolayer expansion by passage 4 versus ∼8-fold in controls. Immunofluorescence quantification revealed significantly elevated Ki67+ /cTnT+ double-positive cardiomyocytes under CHIR treatment (∼20 % vs. ∼9 % in controls at passage 3). Strikingly, proliferative responses showed genetic neutrality: healthy iCMs exhibited ∼432-fold expansion compared to ∼406-fold in disease models (p = 0.72), with comparable Ki67+/cTnT+ ratios by passage 4 (healthy: ∼8.9 %; disease: ∼8.3 %). These findings demonstrate that timed Wnt activation overrides genetic lesions to enable disease-agnostic proliferation in differentiated iCMs. This genetic neutrality supports standardized regenerative strategies for genetically heterogeneous cardiomyopathies and arrhythmias, addressing a critical challenge in developing personalized cardiac therapies.

Publicações recentes

Ver todas no PubMed

📚 EuropePMC560 artigos no totalmostrando 196

2026

Breakthrough ventricular fibrillation in a patient with catecholaminergic polymorphic ventricular tachycardia after a decade of stability: A follow-up report.

HeartRhythm case reports
2026

Ca2+ signalling in cardiac muscle: the importance of balances.

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology
2026

Generation of three heterozygous and two homozygous hiPSC lines from a CPVT associated mutation RYR2_p.G357S from a large family of the Canary Islands.

Stem cell research
2026

Paediatric inherited arrhythmia clinic: developing a new model of care.

BMJ paediatrics open
2026

Listen to your heart and its sympathetic nerves in CPVT.

The Journal of physiology
2026

Neurocardiogenetics: Exploring the association of rare RYR2 variants with neuropsychiatric disorders in general and disease populations.

Journal of neurogenetics
2026

Bidirectional ventricular tachycardia caused by occlusion myocardial infarction-a case report.

European heart journal. Case reports
2026

Ryanodine receptor 2 mutations in catecholaminergic polymorphic ventricular tachycardia: From molecular mechanisms to precision medicine.

World journal of cardiology
2026

Flecainide use before and after the Cardiac Arrhythmia Suppression Trial: A systematic review.

Heart rhythm
2026

Human-derived cardiac-neural microtissues reveal catecholaminergic polymorphic ventricular tachycardia is also a disease of the sympathetic neuron.

The Journal of physiology
2026

[Cardiac arrhythmias-Cellular mechanisms, consequences and challenges in the diagnostics using human models].

Herz
2026

The emerging role of calsequestrin 2: from calcium sensor and modulator to arrhythmia driver.

Journal of physiology and biochemistry
2025

Catecholaminergic Polymorphic Ventricular Tachycardia in a Pregnant Woman.

Maternal-fetal medicine (Wolters Kluwer Health, Inc.)
2026

Long-term follow-up of patients with catecholaminergic polymorphic ventricular tachycardia related to a novel CALM2 variant.

Journal of cardiology cases
2026

Risk stratification for RYR2-mediated catecholaminergic polymorphic ventricular tachycardia: time to broaden the lens.

European heart journal
2026

Corrigendum to: "Gene Therapy for Catecholaminergic Polymorphic Ventricular Tachycardia" [Heart Lung Circ. 32(7), (2023) 790-797.].

Heart, lung &amp; circulation
2026

Finding a new rhythm: child health-related quality of life, parent psychological distress, and unmet needs among families of children with cardiac channelopathies.

Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation
2025

Management of induction of labour and subsequent emergency caesarean birth in a parturient with catecholaminergic polymorphic ventricular tachycardia.

Anaesthesia reports
2025

Catecholaminergic polymorphic ventricular tachycardia mediated by ryanodine receptor 2: a validated risk stratification.

European heart journal
2025

The neuro-cardiac axis in epilepsy.

European journal of internal medicine
2025

Caenorhabditis elegans as an in vivo model system for human inherited primary arrhythmia syndromes.

The Journal of physiology
2025

Introduction of a single carboxylic acid converts the cyclic oligomeric depsipeptide ent-verticilide from a ryanodine receptor 2 (RyR2) inhibitor to RyR2 activator.

Molecular pharmacology
2025

Homozygous and heterozygous penetrance of a missense CASQ2 variant in a South Asian family.

HeartRhythm case reports
2025

Epidemiology of paediatric inherited arrhythmogenic diseases under "Real World" conditions: findings from a 10-year longitudinal study in Eastern Austria.

European journal of pediatrics
2026

Signature ECG part 5: Exercise induced syncope.

Indian pacing and electrophysiology journal
2025

Catecholaminergic polymorphic ventricular tachycardia: A narrative review of recent advances in genetics, mechanisms, diagnosis, and treatment.

Asian heart journal
2026

Comparative investigation of Cx3cr1-Expressing Cardiac Macrophages in Atrioventricular Nodes of Wild-Type and Catecholaminergic Polymorphic Ventricular Tachycardia Mouse Model.

Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology
2025

Neurocognitive Delay in Patients With Catecholaminergic Polymorphic Ventricular Tachycardia.

Circulation. Genomic and precision medicine
2025

RYR2 Exon 3 Deletion as a Cause of Convergent Catecholaminergic Polymorphic Ventricular Tachycardia and Cardiomyopathy.

Circulation. Heart failure
2026

Wnt pathway activation unlocks disease-neutral proliferative potential in human iPSC-derived cardiomyocytes: A comparative study across healthy and inherited cardiac disease models.

Tissue &amp; cell
2025

A Homozygous Mutation (c.241G > A, p.A81T) in the Calsequestrin-2 Causes Eye Defects in Zebrafish.

Biochemical genetics
2025

Calmodulinopathies: the need for a registry.

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology
2025

Cardiac Channelopathies in the Pediatric Patient: The Ryanodine Receptor Related Inherited Cardiac Syndromes.

Cardiac electrophysiology clinics
2026

Optimizing Peri-Operative Pain Management in Children With Long QT Syndrome and Catecholaminergic Polymorphic Ventricular Tachycardia Undergoing Left Cardiac Sympathetic Denervation: A Case Series on Continuous Erector Spinae Plane Block and Serratus Plane Block.

Paediatric anaesthesia
2025

A ryanodine receptor 2 gene variant associated with left ventricular non-compaction, cardiac conduction disease, ventricular arrhythmias, and sudden cardiac death.

Cardiology in the young
2025

Cardiac sympathetic denervation for refractory ventricular arrhythmias in patients with inherited cardiomyopathies.

Heart rhythm
2025

Clustered Regularly Interspaced Short Palindromic Repeats Genome Editing for Cardiovascular Disease: The Future Is Here.

Cardiology in review
2025

Gene Therapy for Inherited Cardiac Arrhythmias.

Journal of cardiovascular translational research
2025

Increased Intermembrane Space [Ca2+] Drives Mitochondrial Structural Damage in CPVT.

Circulation research
2025

CRISPR/Cas9-Based Gene Editing for Correcting Inherited Channelopathies.

Cardiology in review
2025

Direct Therapeutic Modulation of RYR2 Activity by CMYA5.

Circulation
2025

Implantable cardioverter defibrillators for long QT syndrome and catecholaminergic polymorphic ventricular tachycardia? (Not so fast, Louis).

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology
2025

A positive allosteric modulator of the β1AR with antagonist activity for catecholaminergic polymorphic ventricular tachycardia.

The Journal of clinical investigation
2025

Distinct patterns of ventricular fibrillation onset in primary electrical diseases: insights from a retrospective multicentre registry.

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology
2025

Intellectual and Neurodevelopmental Delays in Pediatric Catecholaminergic Polymorphic Ventricular Tachycardia: Distinct Characteristics and a More Malignant Neurocardiac Phenotype.

Circulation. Arrhythmia and electrophysiology
2025

Seizure-Syncope: Clinical implications from two Chinese CPVT children with two novel RYR2 variants.

Gene
2025

CPVT1 point mutations in RyR2 S5 and S6 segments and their Ca2+ signaling consequence.

Cell calcium
2025

Novel Biallelic TECRL Gene Variants Associated with Familial Catecholaminergic Polymorphic Ventricular Tachycardia in a Chinese Family with a History of Sudden Cardiac Death.

The Tohoku journal of experimental medicine
2025

Imagenomics and Ventricular Arrhythmia: The Scar, The Channel, The Variant.

JACC. Case reports
2025

RYR2 Variants in Catecholaminergic Polymorphic Ventricular Tachycardia Patients: Insights From Protein Structure and Clinical Data.

Circulation. Arrhythmia and electrophysiology
2025

The blueprint of neurocardiac crosstalk in arrhythmic syndromes.

American journal of physiology. Cell physiology
2025

Gene Therapy for Cardiac Arrhythmias: Mechanisms, Modalities and Therapeutic Applications.

Medical sciences (Basel, Switzerland)
2025

Comments on "Genetic and clinical characteristics of catecholaminergic polymorphic ventricular tachycardia in a Taiwanese nationwide cohort".

Journal of the Formosan Medical Association = Taiwan yi zhi
2025

A Comprehensive Review of a Mechanism-Based Ventricular Electrical Storm Management.

Journal of clinical medicine
2025

Arrhythmic Risk and Clinical Features in Catecholaminergic Polymorphic Ventricular Tachycardia: Results From a Multicenter Study in Korea.

The American journal of cardiology
2025

Management of channelopathies in children.

Herzschrittmachertherapie &amp; Elektrophysiologie
2025

Unusual catecholaminergic polymorphic ventricular tachycardia and bradycardia caused by a novel triadin variant in 2 siblings from a Malian family.

Medicine
2025

Psychosocial impact of inherited arrhythmia syndromes on anxiety in paediatric patients and their families.

Cardiology in the young
2025

Sudden Cardiac Arrest and Death in Sports: An Updated Overview of Epidemiology, Etiologies, and Prevention Strategies, with Emphasis on Inherited Cardiomyopathies.

Seminars in thrombosis and hemostasis
2025

Compromised repolarization reserve in a murine model of catecholaminergic polymorphic ventricular tachycardia caused by RyR2-R420Q mutation.

Journal of molecular and cellular cardiology
2025

The Diagnostic Value of Copy Number Variants in Genetic Cardiomyopathies and Channelopathies.

Journal of cardiovascular development and disease
2025

Inherited arrhythmia syndromes - Cardiogenetics.

Indian pacing and electrophysiology journal
2025

Disruption of ventricular activation by subthreshold delayed afterdepolarizations in RyR2-R420Q catecholaminergic polymorphic ventricular tachycardia.

Journal of molecular and cellular cardiology plus
2025

Novel causative RYR2 indel variant with exon and intron involvement inducing exon 13 skipping in a family exhibiting catecholaminergic polymorphic ventricular tachycardia.

Frontiers in genetics
2025

Regional Anesthesia With Levobupivacaine in a Patient With a RyR2 Gene Mutation After Cardiac Arrest: A Case Report.

Cureus
2025

Catecholaminergic polymorphic ventricular tachycardia in children-incidence and trends in detection, presentation and management.

Archives of disease in childhood
2025

Demographics, Clinical Features and Genetics of Common Inherited Arrhythmias in Oman.

Journal of the Saudi Heart Association
2025

Simultaneous optical recording of action potentials and calcium transients in cardiac single cells differentiated from type 1 CPVT-iPS cells.

Frontiers in physiology
2025

Updates on inherited arrhythmia syndromes (Brugada syndrome, long QT syndrome, CPVT, ARVC).

Progress in cardiovascular diseases
2025

Catecholaminergic polymorphic ventricular tachycardia and early-onset atrial fibrillation in a tactical athlete with a heterozygous truncating variant in TRDN.

HeartRhythm case reports
2025

Identification of a novel TECRL variant causing type 3 catecholaminergic polymorphic ventricular tachycardia.

Frontiers in pediatrics
2025

Pharmacological Enhancement of Small Conductance Ca2+-Activated K+ Channels Suppresses Cardiac Arrhythmias in a Mouse Model of Catecholaminergic Polymorphic Ventricular Tachycardia.

Circulation research
2025

Catecholaminergic Polymorphic Ventricular Tachycardia in a 16-year-old: Case Report.

Clinical practice and cases in emergency medicine
2025

Outcomes and Burdens to Return-to-Play for Phenotype Negative Athletes With a Genetic Heart Disease.

JACC. Clinical electrophysiology
2025

Sudden Cardiac Death in Pregnant Women-Literature Review and Autopsy Findings.

Diagnostics (Basel, Switzerland)
2025

[Catecholaminergic Polymorphic Ventricular Tachycardia Caused by a Homozygous Pathogenic Variant in Calsequestrin 2 Gene].

Kardiologiia
2025

Unveiling catecholaminergic polymorphic ventricular tachycardia: A case of type 2 ryanodine receptor exon 3 deletion mimicking long QT syndrome type 1.

HeartRhythm case reports
2025

Catecholaminergic polymorphic ventricular tachycardia-linked ryanodine receptor variants exhibit domain-specific calcium leak and calmodulin affinity properties.

The Journal of physiology
2025

Cardiac Channelopathies: Clinical Diagnosis and Promising Therapeutics.

Journal of the American Heart Association
2025

Stellate Ganglia: A Key Therapeutic Target for Malignant Ventricular Arrhythmia in Heart Disease.

Circulation research
2025

Anesthetic Challenges of Labor and Delivery in a Patient With Catecholaminergic Polymorphic Ventricular Tachycardia and Left Ventricular Non-Compaction Cardiomyopathy.

Clinical case reports
2025

Clinical and electrophysiological characterization of a SCN5A gain-of-function mutation associated with CPVT-like arrhythmia.

Journal of molecular and cellular cardiology
2025

Structural Evaluation of RYR2-CPVT Missense Variants and Continuous Bayesian Estimates of their Penetrance.

medRxiv : the preprint server for health sciences
2025

The diagnostic role of pharmacological provocation testing in cardiac electrophysiology: a clinical consensus statement of the European Heart Rhythm Association and the European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the ESC, the ESC Working Group on Cardiovascular Pharmacotherapy, the Association of European Paediatric and Congenital Cardiology (AEPC), the Paediatric & Congenital Electrophysiology Society (PACES), the Heart Rhythm Society (HRS), the Asia Pacific Heart Rhythm Society (APHRS), and the Latin American Heart Rhythm Society (LAHRS).

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology
2025

Heart on Fire: Unmasking RyR2 Mutation in Stress-Induced Ventricular Arrhythmias.

Methodist DeBakey cardiovascular journal
2025

Catecholaminergic Polymorphic Ventricular Tachycardia: Advancing From Molecular Insights to Preclinical Models.

Journal of the American Heart Association
2025

Association of dysautonomia with refractory ventricular tachyarrhythmia in patients requiring thoracoscopic surgical cardiac sympathetic denervation.

JTCVS open
2025

A Different Way to Slow Down in Catecholaminergic Polymorphic Ventricular Tachycardia.

JACC. Clinical electrophysiology
2025

Identification of Mutations of the RYR2 in Sudden Infant Death Syndrome.

Journal of Korean medical science
2025

Non-juvenile familial form of life-threatening arrhythmias caused by the Ryanodine Receptor type 2 c.13823 G>A, p.(Arg4608Gln) pathogenic variant: Atypical catecholaminergic polymorphic ventricular Tachycardia or misdiagnosis?

Forensic science international. Genetics
2025

Arrhythmogenic Potential of Heterozygous TECRL Variants in Type 3 Catecholaminergic Polymorphic Ventricular Tachycardia.

JACC. Clinical electrophysiology
2025

Genetic Background and Clinical Phenotype in an Italian Cohort with Inherited Arrhythmia Syndromes and Arrhythmogenic Cardiomyopathy (ACM): A Whole-Exome Sequencing Study.

International journal of molecular sciences
2025

Incidence and Clinical Management of Supraventricular Arrhythmias in Patients With Catecholaminergic Polymorphic Ventricular Tachycardia.

JACC. Clinical electrophysiology
2025

Prognostic relevance of baseline exercise stress test in RYR2-related CPVT.

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology
2025

A Novel Approach for In Vitro Testing and Hazard Evaluation of Nanoformulated RyR2-Targeting siRNA Drugs Using Human PBMCs.

Life (Basel, Switzerland)
2025

Genetics, manifestations, and management of catecholaminergic polymorphic ventricular tachycardia.

Current opinion in cardiology
2025

Generation of an isogenic CRISPR/Cas9-corrected control induced pluripotent stem cell line from a patient with autosomal dominant catecholaminergic polymorphic ventricular tachycardia with a heterozygous variant in cardiac calsequestrin-2.

Stem cell research
2025

Arrhythmogenic calmodulin variants D131E and Q135P disrupt interaction with the L-type voltage-gated Ca2+ channel (Cav1.2) and reduce Ca2+-dependent inactivation.

Acta physiologica (Oxford, England)
2025

The Role of RyR2 Mutations in Congenital Heart Diseases: Insights Into Cardiac Electrophysiological Mechanisms.

Journal of cardiovascular electrophysiology
2024

Flecainide Specifically Targets the Monovalent Countercurrent Through the Cardiac Ryanodine Receptor, While a Dominant Opposing Ca2+/Ba2+ Current Is Present.

International journal of molecular sciences
2024

Disparate molecular mechanisms in cardiac ryanodine receptor channelopathies.

Frontiers in molecular biosciences
2025

Extracorporeal membrane oxygenation for catecholaminergic polymorphic ventricular tachycardia: a case report and literature review.

BMC pediatrics
2024

Case Report: The unrelenting journey-successful resolution of catecholaminergic polymorphic ventricular tachycardia (CPVT) through right cardiac sympathetic denervation in a teenager after left cardiac sympathetic denervation.

Frontiers in cardiovascular medicine
2024

Catecholaminergic Polymorphic Ventricular Tachycardia in Children: Insights and Challenges From the Current Study.

Korean circulation journal
2024

Treatment Outcomes in Children With Catecholaminergic Polymorphic Ventricular Tachycardia: A Single Institutional Experience.

Korean circulation journal
2026

Influence of age and sex on the diagnostic yield of inherited cardiac conditions in sudden arrhythmic death syndrome decedents.

European journal of preventive cardiology
2025

International Multicenter Cohort Study on Beta-Blocker-Free Treatment Strategies for Catecholaminergic Polymorphic Ventricular Tachycardia Patients.

JACC. Clinical electrophysiology
2024

Dual calcium-voltage optical mapping of regional voltage and calcium signals in intact murine RyR2-R2474S hearts.

Journal of molecular and cellular cardiology plus
2024

Conditional ablation of MCU exacerbated cardiac pathology in a genetic arrhythmic model of CPVT.

Journal of molecular and cellular cardiology plus
2024

A case report of familial catecholaminergic polymorphic ventricular tachycardia with a novel mutation in the ryanodine receptor 2.

European heart journal. Case reports
2024

Voltage Gated Calcium Channel Dysregulation May Contribute to Neurological Symptoms in Calmodulinopathies.

bioRxiv : the preprint server for biology
2024

Exploring Cardiac Sympathetic Denervation as a Treatment Approach for Recurrent Ventricular Arrhythmias: A Concise Review.

Journal of clinical &amp; experimental cardiology
2024

CPVT, PVCs, and Ambulatory Monitoring: Can Old Technology Be Used in New Ways?

JACC. Clinical electrophysiology
2024

The Role of Human-Induced Pluripotent Stem Cells in Studying Cardiac Channelopathies.

International journal of molecular sciences
2024

Copy Number Variants in Cardiac Channelopathies: Still a Missed Part in Routine Arrhythmic Diagnostics.

Biomolecules
2024

Gain-of-Function and Loss-of-Function Mutations in the RyR2-Expressing Gene Are Responsible for the CPVT1-Related Arrhythmogenic Activities in the Heart.

Current issues in molecular biology
2024

Long-term clinical course of patients with catecholaminergic polymorphic ventricular tachycardia: A more than 10-year follow-up cohort study.

Annals of pediatric cardiology
2024

aTrial arrhythmias in inhEriTed aRrhythmIa Syndromes: results from the TETRIS study.

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology
2024

Sudden Cardiac Death and Channelopathies: What Lies behind the Clinical Significance of Rare Splice-Site Alterations in the Genes Involved?

Genes
2024

Electrical storms induced by multiple shocks in catecholaminergic polymorphic ventricular tachycardia, spotlight.

Journal of arrhythmia
2024

Generation of a heterozygous Calsequestrin 2 F189L iPSC line (UMGi158-B) by CRISPR/Cas9 genome editing to investigate the cardiac pathophysiology of Takotsubo Syndrome and Catecholaminergic Polymorphic Ventricular Tachycardia.

Stem cell research
2025

Inhibitors of Intracellular RyR2 Calcium Release Channels as Therapeutic Agents in Arrhythmogenic Heart Diseases.

Annual review of pharmacology and toxicology
2025

Structure-activity optimization of ryanodine receptor modulators for the treatment of catecholaminergic polymorphic ventricular tachycardia.

Heart rhythm
2024

Generation of a human induced pluripotent stem cell line (KSCBi016-A) from a CPVT patient with an RYR2 mutation.

Stem cell research
2024

Idiopathic Ventricular Fibrillation - Just How Much Idiopathic is it?

Reviews in cardiovascular medicine
2024

The Diagnostic Utility of Holter Monitoring in Catecholaminergic Polymorphic Ventricular Tachycardia.

JACC. Clinical electrophysiology
2024

Generation of human induced pluripotent stem cell lines from patients with a RYR2 gene variant c.14201A>G (p.Y4734C): Implications for idiopathic ventricular fibrillation and catecholaminergic polymorphic ventricular tachycardia.

Stem cell research
2024

Induction of ventricular fibrillation during programmed ventricular stimulation in a patient with CASQ2 heterozygous mutation.

Journal of cardiovascular electrophysiology
2024

What an anesthesiologist should know about pediatric arrhythmias.

Paediatric anaesthesia
2024

Assessing the impact and safety of implantable cardioverter defibrillators in treating catecholaminergic polymorphic ventricular tachycardia: a systematic review and meta-analysis protoc.

BMJ open
2024

Cardiac sympathetic denervation for catecholaminergic polymorphic ventricular tachycardia in the light of the medical situation in Japan.

Journal of arrhythmia
2024

Rare Presentation of Wide QRS Tachycardia in a Patient in Their 40s.

Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc
2024

[Catecholaminergic polymorphic ventricular tachycardia (CPVT): an insidious disease that can often lead to sudden cardiac death in young people].

MMW Fortschritte der Medizin
2024

A rare case report of catecholaminergic polymorphic ventricular tachycardia with an uncommon CALM2 mutation.

European heart journal. Case reports
2025

Genetic and clinical characteristics of catecholaminergic polymorphic ventricular tachycardia in a Taiwanese nationwide cohort.

Journal of the Formosan Medical Association = Taiwan yi zhi
2025

Allergy therapy for patients with a cardiac channelopathy: Do not withhold lifesaving treatments.

Heart rhythm
2024

[Cardiac channelopathies in the context of hereditary arrhythmia syndromes].

Innere Medizin (Heidelberg, Germany)
2024

Ion Channel Diseases as a Cause of Sudden Cardiac Death in Young People: Aspects of Their Diagnosis, Treatment, and Pathogenesis.

Deutsches Arzteblatt international
2024

Top stories on catecholaminergic polymorphic ventricular tachycardia (2022-2024).

Heart rhythm
2024

Divergent Biochemical Properties and Disparate Impact of Arrhythmogenic Calmodulin Mutations on Zebrafish Cardiac Function.

Journal of cellular biochemistry
2024

A Clinical Diagnostic Test for Calcium Release Deficiency Syndrome.

JAMA
2024

Molecular Pathways and Animal Models of Arrhythmias.

Advances in experimental medicine and biology
2024

Human Genetics of Cardiac Arrhythmias.

Advances in experimental medicine and biology
2024

Sudden cardiac arrest occurring in temporal proximity to consumption of energy drinks.

Heart rhythm
2024

Diverse Phenotypic Manifestations in a Family with a Novel RYR2 E4107A Variant.

International heart journal
2023

Precision medicine in catecholaminergic polymorphic ventricular tachycardia: Recent advances toward personalized care.

Annals of pediatric cardiology
2024

Novel variants in TECRL leading to catecholaminergic polymorphic ventricular tachycardia.

Life science alliance
2024

Gene therapy with phosphodiesterases 2A and 4B ameliorates heart failure and arrhythmias by improving subcellular cAMP compartmentation.

Cardiovascular research
2024

Novel Compound Heterozygous Variants in Trans-2,3-Enoyl-Coenzyme A Reductase-Like Gene Associated With Catecholaminergic Polymorphic Ventricular Tachycardia.

JACC. Case reports
2024

Dexmedetomidine inhibited arrhythmia susceptibility to adrenergic stress in RyR2R2474S mice through regulating the coupling of membrane potential and intracellular calcium.

Biochemical and biophysical research communications
2024

Mitochondrial Calcium Regulation of Cardiac Metabolism in Health and Disease.

Physiology (Bethesda, Md.)
2024

The importance of variant reinterpretation in inherited cardiovascular diseases: Establishing the optimal timeframe.

PloS one
2024

Catheter Ablation for Channelopathies: When Is Less More?

Journal of clinical medicine
2024

Compliance and complications in catecholaminergic polymorphic ventricular tachycardia.

Heart rhythm
2024

Prognosis and clinical management of asymptomatic family members with RYR2-mediated catecholaminergic polymorphic ventricular tachycardia: a review.

Cardiology in the young
2024

Discovery and Structure-Activity Relationship of a Ryanodine Receptor 2 Inhibitor.

Chemical &amp; pharmaceutical bulletin
2024

An inherited life-threatening arrhythmia model established by screening randomly mutagenized mice.

Proceedings of the National Academy of Sciences of the United States of America
2024

An international multicenter cohort study on implantable cardioverter-defibrillators for the treatment of symptomatic children with catecholaminergic polymorphic ventricular tachycardia.

Heart rhythm
2024

Genetic generalized epilepsy with catecholaminergic polymorphic ventricular tachycardia complicated by ryanodine receptor 2 variant: A case report.

Seizure
2024

A novel RyR2 mutation associated with co-morbid catecholaminergic polymorphic ventricular tachycardia (CPVT) and benign epilepsy with centrotemporal spikes (BECTS).

Journal of electrocardiology
2024

Location of ryanodine receptor type 2 mutation predicts age of onset of sudden death in catecholaminergic polymorphic ventricular tachycardia - A systematic review and meta-analysis of case-based literature.

medRxiv : the preprint server for health sciences
2024

Catecholaminergic Polymorphic Ventricular Tachycardia: Clinical Characteristics, Diagnostic Evaluation and Therapeutic Strategies.

Journal of clinical medicine
2024

Long-term efficacy and safety of cardiac genome editing for catecholaminergic polymorphic ventricular tachycardia.

The journal of cardiovascular aging
2024

RYR2 receptor gene mutation associated with catecholaminergic polymorphic ventricular tachycardia in children: a case report & literature review.

Translational pediatrics
2024

Whole-exome sequencing in familial type 2 diabetes identifies an atypical missense variant in the RyR2 gene.

Frontiers in endocrinology
2024

In Vivo Cardiac Electrophysiology in Mice: Determination of Atrial and Ventricular Arrhythmic Substrates.

Current protocols
2024

Insights into adherence to medication and lifestyle recommendations in an international cohort of patients with catecholaminergic polymorphic ventricular tachycardia.

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology
2024

Primary Electrical Heart Disease-Principles of Pathophysiology and Genetics.

International journal of molecular sciences
2024

A Case Report of Elective Bilateral Proximal Intercostal Blocks Used to Prevent Arrhythmia in Catecholaminergic Polymorphic Ventricular Tachycardia.

A&amp;A practice
2024

Transcriptome analysis of effects of Tecrl deficiency on cardiometabolic and calcium regulation in cardiac tissue.

Open medicine (Warsaw, Poland)
2024

Inherited Arrhythmias in the Pediatric Population: An Updated Overview.

Medicina (Kaunas, Lithuania)
2024

Dual effect of cardiac FKBP12.6 overexpression on excitation-contraction coupling and the incidence of ventricular arrhythmia depending on its expression level.

Journal of molecular and cellular cardiology
2023

Early-onset cardiac arrest, prolonged QT interval, and left ventricular hypertrophy: Phenotypic manifestations of a pathogenic de novo calmodulin variant.

HeartRhythm case reports
2023

Catecholaminergic Polymorphic Ventricular Tachycardia: Multiple Clinical Presentations of a Genetically Determined Disease.

Journal of clinical medicine
2024

The proarrhythmogenic role of autonomics and emerging neuromodulation approaches to prevent sudden death in cardiac ion channelopathies.

Cardiovascular research
2023

Dual-Dye Optical Mapping of Hearts from RyR2 R2474S Knock-In Mice of Catecholaminergic Polymorphic Ventricular Tachycardia.

Journal of visualized experiments : JoVE
2024

The Relationship Between Ventilatory Anaerobic Threshold and Arrhythmia in Patients With Catecholaminergic Polymorphic Ventricular Tachycardia.

JACC. Clinical electrophysiology
2023

Smooth Emergence from General Anesthesia after Deep Extubation in a Pediatric Patient Diagnosed with Catecholaminergic Polymorphic Ventricular Tachycardia: A Case Report.

Medicina (Kaunas, Lithuania)
2023

The Structural-Functional Crosstalk of the Calsequestrin System: Insights and Pathological Implications.

Biomolecules
2023

Assessment of Sudden Cardiac Death Risk in Pediatric Primary Electrical Disorders: A Comprehensive Overview.

Diagnostics (Basel, Switzerland)
2023

Electrophysiological Characteristics and Ablation Outcomes in Patients With Catecholaminergic Polymorphic Ventricular Tachycardia.

Journal of the American Heart Association
2024

Application and validation of phenotype-enhanced variant classification in East Asian patients with catecholaminergic polymorphic ventricular tachycardia.

Heart rhythm
2023

Clinical and genetic profiles of chinese pediatric patients with catecholaminergic polymorphic ventricular tachycardia.

Orphanet journal of rare diseases
2023

Focal atrial tachycardia mimicking catecholaminergic polymorphic ventricular tachycardia: a case report.

European heart journal. Case reports
2023

Catecholaminergic Polymorphic Ventricular Tachycardia and Gene Therapy: A Comprehensive Review of the Literature.

Cureus
2023

Insights on the mechanism of flecainide in catecholaminergic polymorphic ventricular tachycardia.

Journal of medicine and life
2023

Exercise-Induced Ventricular Tachycardia: A Case Report.

Cureus
2023

Anesthetic Management for Dental Extraction in a Patient With Catecholaminergic Polymorphic Ventricular Tachycardia Syndrome: A Case Report.

Cureus
2024

Clinical and genetic characteristics of catecholaminergic polymorphic ventricular tachycardia combined with left ventricular non-compaction.

Cardiology in the young
2024

Catecholaminergic polymorphic ventricular tachycardia (and seizure) caused by a novel homozygous likely pathogenic variant in CASQ2 gene.

Gene
2023

Flecainide Is Associated With a Lower Incidence of Arrhythmic Events in a Large Cohort of Patients With Catecholaminergic Polymorphic Ventricular Tachycardia.

Circulation
2023

Broad and narrow complex tachycardia resulting in cardiorespiratory arrest in a child: what is the optimal treatment strategy?

European heart journal. Case reports
2023

Survival in a young child with out-of-hospital cardiac arrest: diagnostic dilemma and when to deviate from standard resuscitation guidelines.

BMJ case reports
2022

Life-threatening cardiac arrhythmia and sudden death during electronic gaming: An international case series and systematic review.

Heart rhythm
2023

Sudden pediatric cardiac arrest with catecholaminergic polymorphic ventricular tachycardia: When epinephrin should be avoided.

Resuscitation
2023

Screening for Novel Type 2 Ryanodine Receptor Inhibitors by Endoplasmic Reticulum Ca2+ Monitoring.

Molecular pharmacology
Ver todos os 560 no EuropePMC

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Taquicardia ventricular polimórfica catecolaminérgica.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Taquicardia ventricular polimórfica catecolaminérgica

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. Ca2+ signalling in cardiac muscle: the importance of balances.
    Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology· 2026· PMID 41824801mais citado
  2. Generation of three heterozygous and two homozygous hiPSC lines from a CPVT associated mutation RYR2_p.G357S from a large family of the Canary Islands.
    Stem cell research· 2026· PMID 41819740mais citado
  3. Paediatric inherited arrhythmia clinic: developing a new model of care.
    BMJ paediatrics open· 2026· PMID 41802778mais citado
  4. Bidirectional ventricular tachycardia caused by occlusion myocardial infarction-a case report.
    European heart journal. Case reports· 2026· PMID 41704835mais citado
  5. Wnt pathway activation unlocks disease-neutral proliferative potential in human iPSC-derived cardiomyocytes: A comparative study across healthy and inherited cardiac disease models.
    Tissue &amp; cell· 2026· PMID 41242031mais citado
  6. Two novel ryanodine receptor 2 mutations associated with catecholaminergic polymorphic ventricular tachycardia in children: two case reports and literature review.
    Cardiol Young· 2026· PMID 41987505recente
  7. Imaging and safety profiling of inhaled siRNA RyR2 in human respiratory models.
    Arch Toxicol· 2026· PMID 41984094recente
  8. Unexpected Pediatric Cardiac Arrest in a Toddler: A Case of Catecholaminergic Polymorphic Ventricular Tachycardia Presenting as Ventricular Fibrillation.
    Pediatr Emerg Care· 2026· PMID 41968876recente
  9. Refractory Atrial Tachycardia and Ivabradine in a Case of Catecholaminergic Polymorphic Ventricular Tachycardia.
    Turk Kardiyol Dern Ars· 2026· PMID 41961118recente
  10. Novel RYR2-A4510T Variant Presenting Both as Autosomal Dominant and Autosomal Recessive Catecholaminergic Polymorphic Ventricular Tachycardia.
    Circ Genom Precis Med· 2026· PMID 41958394recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:3286(Orphanet)
  2. MONDO:0017990(MONDO)
  3. GARD:4421(GARD (NIH))
  4. Variantes catalogadas(ClinVar)
  5. Busca completa no PubMed(PubMed)
  6. Q1649897(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Taquicardia ventricular polimórfica catecolaminérgica
Compêndio · Raras BR

Taquicardia ventricular polimórfica catecolaminérgica

ORPHA:3286 · MONDO:0017990
Prevalência
1-5 / 10 000
Herança
Autosomal dominant, Autosomal recessive
CID-10
I47.2 · Taquicardia ventricular
CID-11
Ensaios
8 ativos
Início
Adolescent, Adult, Childhood
Prevalência
10.0 (Europe)
MedGen
UMLS
C5574922
EuropePMC
Wikidata
Papers 10a
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades